company background image
AXDX

Accelerate Diagnostics NasdaqCM:AXDX Stock Report

Last Price

US$1.65

Market Cap

US$163.4m

7D

7.1%

1Y

-70.8%

Updated

06 Oct, 2022

Data

Company Financials +
AXDX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth1/6
Past Performance0/6
Financial Health0/6
Dividends0/6

AXDX Stock Overview

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East.

Accelerate Diagnostics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Accelerate Diagnostics
Historical stock prices
Current Share PriceUS$1.65
52 Week HighUS$7.19
52 Week LowUS$0.50
Beta1.35
1 Month Change5.10%
3 Month Change41.03%
1 Year Change-70.85%
3 Year Change-90.90%
5 Year Change-91.67%
Change since IPO931.25%

Recent News & Updates

Aug 30

Accelerate Diagnostics spikes as Chief Technology Officer raises stake

The shares of in vitro diagnostics firm Accelerate Diagnostics, Inc. (NASDAQ:AXDX) jumped Tuesday after its Chief Technology Officer Larry Michael Mertz announced the purchase of 50K company shares. According to a regulatory filing today, Mr. Mertz bought $80K worth of AXDX shares at $1.60 apiece on Aug. 30, raising his stake by ~13%. The latest transaction comes a week after Mr. Mertz added ~51.7K AXDX shares, increasing his ownership in the company by ~16%. Mertz has served as the Senior Vice President, Head of R&D at AXDX since May 2021. The insider trading comes after the company recently announced a public offering of 17.5M shares of common stock at $2.00 per share. The share issuance was expected to raise $35M in gross proceeds for general corporate purposes and commercialization efforts.

Aug 20
Need To Know: Analysts Are Much More Bullish On Accelerate Diagnostics, Inc. (NASDAQ:AXDX)

Need To Know: Analysts Are Much More Bullish On Accelerate Diagnostics, Inc. (NASDAQ:AXDX)

Accelerate Diagnostics, Inc. ( NASDAQ:AXDX ) shareholders will have a reason to smile today, with the analysts making...

Shareholder Returns

AXDXUS Medical EquipmentUS Market
7D7.1%3.5%3.3%
1Y-70.8%-27.5%-20.4%

Return vs Industry: AXDX underperformed the US Medical Equipment industry which returned -25.9% over the past year.

Return vs Market: AXDX underperformed the US Market which returned -18.8% over the past year.

Price Volatility

Is AXDX's price volatile compared to industry and market?
AXDX volatility
AXDX Average Weekly Movement24.1%
Medical Equipment Industry Average Movement8.6%
Market Average Movement6.9%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.9%

Stable Share Price: AXDX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 24% a week.

Volatility Over Time: AXDX's weekly volatility (24%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1982220Jack Phillipshttps://acceleratediagnostics.com

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk.

Accelerate Diagnostics, Inc. Fundamentals Summary

How do Accelerate Diagnostics's earnings and revenue compare to its market cap?
AXDX fundamental statistics
Market CapUS$163.45m
Earnings (TTM)-US$63.78m
Revenue (TTM)US$13.29m

12.3x

P/S Ratio

-2.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AXDX income statement (TTM)
RevenueUS$13.29m
Cost of RevenueUS$13.74m
Gross Profit-US$449.00k
Other ExpensesUS$63.33m
Earnings-US$63.78m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.64
Gross Margin-3.38%
Net Profit Margin-480.03%
Debt/Equity Ratio-170.9%

How did AXDX perform over the long term?

See historical performance and comparison